Substantive comments clinical observations with denominators, safety monitoring, validated quality methods can change what the committee sees
As recent studies show the amount of people taking glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for weight loss, and not for managing type 2 diabetes as originally used, researchers have been examining these medications for potential positive and negative side effects
Simultaneously, tirzepatide suppresses glucagon secretion, which helps prevent the liver from releasing excess glucose into the bloodstream
However, retatrutide is still under study and not yet FDA-approved, while semaglutide is widely available and approved for both weight loss and diabetes management
Go deeper Explore the Peptides Guide Complete Peptides Guide: BPC-157, GHK-CU, GLP-1 Read the guide What Is GHK-CU